Industry News

      Cortexyme Announces Clinical Hold on Atuzaginstat’s Investigational New Drug Application

      SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on Alzheimer’s and other degenerative diseases, today announced that the company...

      Labcorp to Offer Risk-Scoring Test for People With Advanced Liver Fibrosis Due to NASH

      BURLINGTON, N.C.--(BUSINESS WIRE)--For the millions of people in the United States living with an advanced form of chronic liver disease, simply understanding the potential...

      Melanoma Research Alliance Statement on FDA Approval of Tebentafusp, the First Drug for Treating Metastatic Uveal Melanoma

      WASHINGTON--(BUSINESS WIRE)--The Melanoma Research Alliance (MRA) released the following statements from MRA Chief Science Officer Marc Hurlbert, PhD and MRA President & CEO Michael...

      NANOBIOTIX Announces Publication of New Preclinical Immunotherapy Data Showcasing the Combination Potential of NBTXR3 With anti-PD-1 and anti-CTLA-4

      PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’) (Paris:NANO) (NASDAQ:NBTX), a late-stage clinical biotechnology company pioneering physics-based approaches...

      Recent Articles

      Get a free copy of "Cracking the Generics Code"

      Looks like you are using an ad-blocking browser extension. We request you to whitelist our website on the ad-blocking extension and refresh your browser to view the content.